Ken Griffin Vaxart, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.58 - $0.99 $3,537 - $6,039	-6,100 Reduced 8.48%	65,800 $55,000
Q2 2024 Aug 14, 2024	BUY	$0.53 - $1.3 $3,021 - $7,410	5,700 Added 8.61%	71,900 $48,000
Q1 2024 May 15, 2024	SELL	$0.56 - $1.41 $63,448 - $159,753	-113,300 Reduced 63.12%	66,200 $86,000
Q4 2023 Feb 14, 2024	SELL	$0.57 - $0.85 $1,083 - $1,615	-1,900 Reduced 1.05%	179,500 $102,000
Q3 2023 Nov 14, 2023	SELL	$0.69 - $0.85 $23,046 - $28,390	-33,400 Reduced 15.55%	181,400 $136,000
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.41 $14,700 - $34,545	-24,500 Reduced 10.24%	214,800 $156,000
Q1 2023 May 15, 2023	SELL	$0.71 - $1.25 $170,400 - $300,000	-240,000 Reduced 50.07%	239,300 $181,000
Q4 2022 Feb 14, 2023	SELL	$0.75 - $2.24 $225 - $672	-300 Reduced 0.06%	479,300 $460,000
Q3 2022 Nov 14, 2022	SELL	$2.09 - $4.5 $191,653 - $412,650	-91,700 Reduced 16.05%	479,600 $1.05 Million

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.